Blood levels of a nerve cell-derived component known as neurofilament light chain (NfL) could be used as a biomarker of disease severity and treatment response in patients with relapsing-remitting ... Read more
A request for a potential cannabis-based treatment for multiple sclerosis to be given Fast Track designation, speeding its development as it readies to enter clinical testing, is now before the U.S. Food and Drug Administration ... Read more
Early-life use of antibiotics disrupts gut microbiota in a rat model of multiple sclerosis (MS) and provokes nervous system autoimmunity, ultimately aggravating disease severity, new research shows. Results also indicate ... Read more
A protein called MMP-9 could be a predictive marker of progressive multifocal leukoencephalopathy development in patients with relapsing-remitting multiple sclerosis (RRMS) who are being treated with Tysabri (natalizumab), a study suggests.
The study, ... Read more
Issues with social cognition can occur in relapsing-remitting multiple sclerosis (RRMS) patients even without the presence of cognitive impairment, and are related to damage in a specific brain region known ... Read more
The Physicians’ Education Resource will host an interactive, case-based discussion on the latest therapeutics in multiple sclerosis (MS). The free educational program, part of the 2019 Americas Committee for Treatment and ... Read more
Previously unknown immune cell subtypes are present in the inflamed brain of mice models of multiple sclerosis, a new study reports.
According to the researchers, these subsets of myeloid cells ... Read more
Rehabilitation using traditional dysphagia therapy improved swallowing function in multiple sclerosis patients with dysphagia, a pilot study shows.
Traditional dysphagia therapy, also known as TDT, is a potential rehabilitation strategy ... Read more
Awareness of certain symptoms, particularly gait disorders and depression, could be critical for reducing the time it takes to diagnose multiple sclerosis (MS) after a patient first contacts a healthcare ... Read more
Patients with relapsing-remitting multiple sclerosis (RRMS), particularly those with multiple conditions who are more severely disabled, are more likely to be using several medications at the same time, a study ... Read more
Anxiety and depression are associated with lower cognitive abilities in patients with multiple sclerosis other and immune-mediated inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis, a study shows.
These ... Read more
Multiple sclerosis (MS) patients in Canada are more likely to comply with their treatment plan and less likely to discontinue the use of the oral disease-modifying treatment Gilenya (fingolimod), compared ... Read more
The progressive decline in brain volume in multiple sclerosis (MS) patients, despite treatment with the disease-modifying therapy Tysabri (natalizumab), is driven by atrophy — shrinkage due to the degeneration of cells ... Read more
Subpopulations of oligodendrocytes — cells that produce the myelin sheath that protects nerve fibers — are altered in patients with multiple sclerosis, a study shows. These findings suggest that oligodendrocyte ... Read more
GeNeuro has reported positive data from a Phase 1 clinical trial (NCT03574428) evaluating the safety and tolerability of high doses of GNbAC1, developed for the treatment of neurological and autoimmune disorders, ... Read more
Naboso Technology has expanded its product offerings with new insoles and training mats specifically designed to stimulate the nervous system through the skin on the bottom of the feet. The ... Read more
Novartis and the University of Oxford’s Big Data Institute (BDI) have established an alliance to advance the use of medical data for spotting disease patterns and assessing patients’ responses to ... Read more
Initial treatment of relapsing-remitting multiple sclerosis (RRMS) with Gilenya (fingolimod), Tysabri (natalizumab), or Lemtrada (alemtuzumab) is associated with a lower risk of conversion to secondary progressive multiple sclerosis (SPMS), ... Read more
Fatigue is more prevalent among patients with progressive multiple sclerosis (MS), according to a study that surveyed patients on fatigue and factors related to it. In addition, increased fatigue ... Read more
A small molecule called Sephin1 may be able to significantly delay harm to neurons in multiple sclerosis (MS) by protecting oligodendrocytes, limiting the autoimmune response, a mouse study reports.
The study, ... Read more
Katerina Akassoglou, PhD, a leading neurology researcher at the Gladstone Institutes at the University of California, San Francisco (UCSF), won the 2018 Barancik Prize for Innovation in Multiple Sclerosis ... Read more
Tecfidera (dimethyl fumarate) demonstrated strong efficacy in Japanese and other East Asian patients with relapsing-remitting multiple sclerosis (RRMS), a Phase 3 clinical trial shows.
These results are consistent with previous ... Read more
BrainStorm Cell Therapeutics announced that the production of its therapy NurOwn will be expanded to support upcoming clinical trials, namely a Phase 3 trial in amyotrophic lateral sclerosis (ALS) and a ... Read more
Pin It on Pinterest